QT Imaging Releases Next-Gen Reconstruction Software Enhancing Breast Imaging

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 2 hours ago

0mins

QTI+2.21%

Should l Buy QTI?

Source: Newsfilter

Image Quality Improvement: QT Imaging's latest version 4.5.0 reconstruction software significantly enhances spatial resolution in reflection imaging by implementing optimized spatially varying deconvolution, resulting in more accurate image representation while maintaining processing efficiency, thereby improving clinical image usability and interpretability.
Expanded Clinical Applications: The new software version improves image reconstruction for small breasts and provides more accurate assessments of fibroglandular tissue composition in breasts with implants, addressing important clinical scenarios and broadening the software's usability across diverse patient anatomies, thus enhancing clinical decision support capabilities.
Multimodal Imaging Advancement: QT Imaging is advancing the development of attenuation as an additional quantitative biomarker, complementing speed of sound and reflection intensity, which is expected to further enhance tissue characterization capabilities and provide clinicians and researchers with additional quantitative information for improved analysis and decision support.
Commitment to Continuous Innovation: These technological advancements reflect QT Imaging's ongoing focus on improving image quality, clinical reliability, and workflow efficiency, marking another significant step in the company's development of advanced imaging software solutions aimed at enhancing global health outcomes.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy QTI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on QTI

Wall Street analysts forecast QTI stock price to rise

0 Analyst Rating

0 Buy

0 Hold

0 Sell

Current: 5.870

Low

Averages

High

Current: 5.870

Low

Averages

High

Lake Street

NULL

Buy

initiated

$10

2026-01-30

Reason

Lake Street

Price Target

$10

AI Analysis

2026-01-30

initiated

NULL

Buy

Reason

Lake Street initiated coverage of QT Imaging with a Buy rating and $10 price target. The company's QT Scan delivers true 3D imaging of breast tissue and offers unique characteristics, making it highly attractive to patients and clinicians, the analyst tells investors. The "massive homerun opportunity" for QT is to become a significant modality within breast cancer screening, the analyst added.

About QTI

QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

QT Imaging Files $100M Mixed Securities Shelf Registration

1 day agoseekingalpha

Securities Shelf Filing: QT Imaging has filed a $100 million mixed securities shelf registration, which, while not an offer to sell, indicates the company's active engagement in capital markets and may pave the way for future financing opportunities.
Financial Performance: The company reported a GAAP EPS of -$0.10 and revenue of $8.28 million, and despite the losses, QT Imaging reaffirmed its FY26 outlook, demonstrating confidence in future growth prospects.
Preliminary Financial Data: Preliminary figures show a GAAP EPS of -$0.10 with revenue slightly increasing to $8.3 million, indicating the company's stability in the market, although it still faces challenges in achieving profitability.
Quant Rating Insight: Seeking Alpha's Quant Rating on QT Imaging provides context with historical financial data, revealing that despite current underperformance, there remains a divergence in market perceptions regarding the company's future potential.